Sinopep-Allsino Biopharmaceutical Revenue

Pharmaceutical Manufacturing • Haizhou, Jiangsu, China • 21-50 Employees

Sinopep-Allsino Biopharmaceutical revenue & valuation

Annual revenue	$1,796,655
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues	$5,800,000
Total funding	No funding

Key Contacts at Sinopep-Allsino Biopharmaceutical

Ella Guo

Director Of Business Development

Connor Thomson

Director Of Peptides

Sinopep Api Manufacturer

Director Of Business Development

Hongfei Yin

Director Of Chemical Process R&D

Jessie Xiang

Director Of Business Development

Wenxian Pan

Senior Director

Wilson Gu

Director Environment Health Safety

Company overview

Headquarters	Haizhou, Jiangsu, China
Website	sinopep.com
NAICS	3254
Keywords	Regulatory Compliance, Oligonucleotides, Advanced Manufacturing Technologies, Innovative Drug Development, Therapeutic Peptides, Comprehensive Documentation, Industry Standards Compliance, Pharmaceutical Excellence, End-To-End Crdmo Services, Exclusive Api Supplier, Flexible Manufacturing Solutions, High-Demand Peptide Products, Large-Scale Batch Manufacturing, Pharmaceutical And Healthcare Industries, Small Molecular, Synthetic Conjugates, Trusted Industry Partner
Founded	2009
Employees	21-50

Sinopep-Allsino Biopharmaceutical Email Formats

Sinopep-Allsino Biopharmaceutical uses 1 email format. The most common is {first initial} (e.g., j@sinopep.com), used 100% of the time.

Format	Example	Percentage
{first initial}	j@sinopep.com	100%

About Sinopep-Allsino Biopharmaceutical

Sinopep is a trusted CDMO specializing in end-to-end CMC development and cGMP manufacturing of peptide and oligonucleotide APIs for NCEs, from early-phase development to commercialization. Since 2009, Sinopep has passed four U.S. FDA inspections and adheres strictly to FDA/ICH guidelines. Our expertise covers process and analytical method development/validation, stability studies, and regulatory support for global filings (IND/NDA). Beyond NCEs, we are the top global supplier of Semaglutide, Tirzepatide, and Liraglutide, leading in export volume. With one of the world's largest and most flexible production capacities, Sinopep supports projects from milligram-scale discovery to 200+ kg commercial batches. By prioritizing early-phase CMC readiness—including Phase 3-ready packages by Phase 2b—we accelerate timelines for fast-track and breakthrough therapies.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Director

Entry

Manager

Employees by Department

Sinopep-Allsino Biopharmaceutical has 12 employees across 4 departments.

Departments

Number of employees

Funding Data

Sinopep-Allsino Biopharmaceutical has never raised funding before.

Frequently asked questions

Sinopep-Allsino Biopharmaceutical is located in Haizhou, Jiangsu, CN.

Sinopep-Allsino Biopharmaceutical generates an estimated annual revenue of $1,796,655. This revenue figure reflects the company's market position and business performance in its industry.

Sinopep-Allsino Biopharmaceutical has an estimated valuation of $5,800,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Sinopep-Allsino Biopharmaceutical was founded in 2009, making it 17 years old. The company has established itself as a significant player in its industry over this time.

Sinopep-Allsino Biopharmaceutical has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Key Contacts at Sinopep-Allsino Biopharmaceutical

Ella Guo

Director Of Business Development

Connor Thomson

Director Of Peptides

Sinopep Api Manufacturer

Director Of Business Development

Hongfei Yin

Director Of Chemical Process R&D

Jessie Xiang

Director Of Business Development

Wenxian Pan